State Street Corp Has $77.07 Million Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

State Street Corp boosted its stake in Evolent Health, Inc. (NYSE:EVH) by 1.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,725,375 shares of the technology company’s stock after purchasing an additional 25,967 shares during the quarter. State Street Corp owned about 2.34% of Evolent Health worth $77,074,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Covestor Ltd increased its holdings in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC increased its holdings in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after purchasing an additional 1,556 shares during the last quarter. Quarry LP bought a new stake in Evolent Health in the second quarter valued at about $32,000. Canada Pension Plan Investment Board bought a new stake in Evolent Health in the second quarter valued at about $61,000. Finally, Quest Partners LLC bought a new stake in Evolent Health in the second quarter valued at about $87,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EVH. Truist Financial restated a “buy” rating and issued a $33.00 price target on shares of Evolent Health in a report on Tuesday, August 27th. Citigroup lowered their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Stephens downgraded Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $38.00 to $16.00 in a report on Friday, November 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $20.00 price objective on shares of Evolent Health in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. decreased their price objective on Evolent Health from $45.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Evolent Health has a consensus rating of “Buy” and a consensus target price of $26.18.

Evolent Health Stock Performance

Shares of NYSE EVH opened at $10.87 on Wednesday. The stock has a 50 day moving average price of $17.59 and a 200 day moving average price of $22.38. Evolent Health, Inc. has a 52 week low of $10.70 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $1.27 billion, a PE ratio of -11.95 and a beta of 1.45.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.